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iIntroduction
Systemic  Lupus  Erythematosus  (SLE)  is  a  multisystemic
autoimmune  disease  of  unknown  origin  with  a  waxing  and
waning  course  and  a  signiﬁcant  morbi-mortality.  The  objec-
tive  of  this  paper  is  to  provide  an  SLE  overview,  as  well
as  recommendations  regarding  diagnosis  and  therapeutic
concepts.  In  the  ﬁrst  stage  of  the  disease,  the  combina-
tion  of  genetic,  gender  and  environmental  factors  culminate
in  the  formation  of  autoantibodies  years  before  the  onset
of  symptoms  is  observed.  In  the  second  phase,  there  are
clinical  manifestations  and  associations  with  comorbidities.
Management  of  patients  with  SLE  should  be  predictive,  pre-
ventive,  personalized,  and  participatory  in  order  to  achieve
remission  and  prevent  relapses.  We  can  divide  SLE  into
three  categories  according  to  the  severity  of  the  disease:
mild,  moderate,  and  severe.  Corticosteroids  are  the  main-
stay  of  therapy,  but  the  use  of  another  agent  is  mandatory  in
order  to  reduce  side  effects.  Some  of  the  biological  agents
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ethotrexate,  antimalarials,  azathioprine,  mycophenolate
ofetil,  cyclophosphamide,  belimumab  and  rituximab.
ackground
iagnosing  Systemic  Lupus  Erythematosus  (SLE)  has  been  a
hallenge  over  the  years.  The  ﬁrst  reports  of  the  disease
nly  considered  skin  manifestations.  Later,  William  Osler
ecognized  the  systemic  involvement  of  the  disease.1 SLE
s  a multisystemic  autoimmune  disease  of  unknown  origin.2
LE  has  an  incidence  of  1--10  per  100,000  person-years  and
 prevalence  of  20--70  per  100,000  inhabitants.3 SLE  preva-
ence  in  Hispanics  is  138.7--244.5  per  100,000  people.4 For
very  9--10  women  with  SLE,  1  male  will  be  affected.2 SLE
as  a waxing  and  waning  course  with  signiﬁcant  morbidity
hat  can  be  fatal  --  if  not  treated  early  --  in  some  patients.
 diagnosis  of  SLE  should  be  considered  when  a  patient  has
haracteristic  features  of  SLE  associated  with  autoantibody
ormation5;  thus,  the  presence  of  anti-nuclear  antibodies
ANA)  is  considered  necessary  for  an  SLE  diagnosis.  Patients
ithout  ANA  will  have  less  than  a  3%  probability  of  develop-
ng  the  disease.
The  objectives  of  this  paper  are  to  provide  an  overviewased  on  the  literature  and  on  the  personal  experience  of
0  years  of  treating  patients  with  SLE,  provide  general  and
peciﬁc  recommendations  regarding  the  diagnosis  of  this
hallenging  disease,  and  share  therapeutic  concepts  that
asson Doyma México S.A. All rights reserved.
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Susceptibility:
Genetic
Gender
Environmental
Autoantibodies
Latent lupus
Incomplete lupus
Preclinical phase Clinical phase
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Table  1  General  recommendations  for  SLE* patients.
Balanced  diet  and  exercise
Avoid  substances  and  drugs  that  might  induce  lupus
No smoking
Vaccination  schedule
Assessment  of  cardiovascular  risk  factors
Screening  of  cancer
Evaluation  of  reproductive  health
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ligure  1  Proposed  current  stages  for  developing  clinical  man-
festations  of  Systemic  Lupus  Erythematosus.
re  fundamental  for  the  comprehensive  management  of  the
isease.
LE stages
LE  stages  include  a  preclinical  and  a  clinical  phase,  as  well
s  its  related  comorbidities.
Clinical  manifestations  only  develop  in  predisposed  indi-
iduals  and  are  secondary  to  a  loss  of  tolerance  with  a
ubsequent  immune  dysregulation6 (Fig.  1).  The  develop-
ent  of  autoimmunity  is  determined  by  genetic,  gender,
nd  environmental  factors.  Advances  in  genetic  techniques
ave  identiﬁed  more  than  30  genetic  associations  with  SLE
ncluding  variants  of  HLA  and  Fc  receptor  genes,  IRF5,
TAT4,  PTPN22,  TNFAIP3,  BLK,  BANK1,  TNFSF4  and  ITGAM.7
oreover,  the  genetic  contribution  to  the  development
f  SLE  has  been  observed  in  twins,  with  a  concordance
etween  monozygotic  twins  of  24--56%  vs  2--5%  in  dizy-
otic  twins.8 Female  preponderance  in  the  pathogenesis
f  SLE  has  been  demonstrated  in  transgenic  mice.  Smith-
ouvier  et  al.  observed  that  mice  with  the  XX  chromosome
ere  more  susceptible  to  developing  lupus  when  compared
o  XY  mice.9 Environmental  factors  can  contribute  to  the
evelopment  of  SLE  by  the  inhibition  of  DNA  methylation.10
hese  factors  include  drugs  (e.g.  procainamide),  diet,  smok-
ng,  UV  light  exposure  and  infections  (Epstein--Barr  virus).11
inally,  there  is  a  pathogenic  autoantibody  production  in  SLE
atients,  reﬂecting  loss  of  tolerance.6
Different  authors  have  described  the  development  of
utoantibodies  before  the  clinical  onset  of  the  disease
n  the  past.  Arbuckle  et  al.  described  the  presence  of
t  least  one  SLE  autoantibody  before  the  diagnosis  (up
o  9.4  years  earlier;  mean,  3.3  years)  in  asymptomatic
atients.  Antinuclear,  antiphospholipid,  anti-Ro  and  anti-La
ntibodies  preceded  the  other  autoantibodies  in  this  cohort
f  patients.12 Subsequently,  McClain  et  al.  described  the
linical  signiﬁcance  of  the  presence  of  antiphospholipid  anti-
odies  prior  to  an  SLE  diagnosis,  as  well  as  the  presence  of
hese  autoantibodies  in  patients  with  a  more  severe  clinical
utcome.13
In  order  to  classify  patients  in  the  early  stages  of  the  dis-
ase,  different  authors  have  proposed  deﬁnitions  according
a
S
aAssessment  of  cognitive  function
* Systemic lupus erythematosus.
o  the  symptoms  and  the  presence  of  classiﬁcation  criteria.
irst,  the  term  undifferentiated  connective  tissue  disease
UCTD)  is  used  in  individuals  with  a disease  manifestation
uggestive  but  not  diagnostic  of  a  speciﬁc  connective  tis-
ue  disease.  UCTD  accounts  for  10--20%  of  referred  patients,
0--15%  will  fulﬁll  the  classiﬁcation  criteria  for  SLE  5  years
ater.14 Factors  that  predict  evolution  to  SLE  are  young
ge,  alopecia,  serositis,  discoid  lupus,  a  positive  anti-human
lobulin  (Coombs)  test  and  anti-Sm  or  anti-DNA  antibodies.15
Ganczarczyk  et  al.  described  the  term  ‘‘latent  lupus’’  to
eﬁne  patients  with  features  consistent  with  SLE  which  may
r  may  not  be  a  part  of  the  American  College  of  Rheumato-
ogy  (ACR)  classiﬁcation  criteria,  but  still  are  ≤4.16
Incomplete  lupus  refers  to  patients  with  less  than  four
CR  classiﬁcation  criteria  for  SLE.  Swaak  et  al.  in  a  multicen-
ric  study,  observed  that  only  three  of  122  incomplete  lupus
atients  developed  SLE  during  3  years  of  follow-up,  and  sug-
ested  that  incomplete  SLE  forms  a  subgroup  with  a  good
rognosis.17 Later,  Greer  et  al.  conﬁrmed  this  observation.
hey  followed  38  incomplete  lupus  patients  over  19  months
nd  only  two  developed  SLE.18 An  additional  term  is  preclin-
cal  lupus,  which  deﬁnes  individuals  with  increased  genetic
isk  for  the  development  of  SLE  but  no  clinical  symptoms.19
After  the  preclinical  stage,  the  clinical  stage  occurs  with
he  onset  of  symptoms.  The  GLADEL  (Grupo  Latinoameri-
ano  de  Estudio  de  Lupus)  cohort,  a  multinational  inception
rospective  cohort  in  Latin  American  centers,  described  the
ymptoms  in  1214  patients  with  SLE.  They  found  that  arthral-
ia  and/or  arthritis,  fever,  photosensitivity,  alopecia  and
alar  rash  were  the  most  common  symptoms  at  onset.20
LE treatment
LE  management  represents  the  ‘‘P4’’,  a  new  paradigm  of
odern  medicine.  P4  Medicine  stands  for  Predictive,  Pre-
entive,  Personalized  and  Participatory  Medicine.
SLE  is  a  syndrome  with  high  variability  in  the  disease
ourse  as  well  as  in  the  severity  of  the  manifestations;
herefore  each  SLE  patient  should  be  treated  on  an  individ-
alized  basis  in  order  to  implement  a  proper  treatment.21
he  goal  of  the  treatment  is  to  achieve  remission,  prevent
ares  and  use  of  drugs  with  the  minimum  dose  required
o  prevent  long-term  side  effects.  The  treatment  includes
ifestyle  modiﬁcation,  patient  education,  physical  activity
nd  medical  or  (in  some  cases)  surgical  intervention.
There  are  general  recommendations  that  are  given  to
LE  patients  (Table  1).  All  patients  should  have  a  bal-
nced  diet  and  exercise  regularly.  Patients  are  advised  to
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Disease severity
Mild
Malar rash
Arthralgia
Fatigue
Sun protection
Antimalarials
NSAID
Analgesics
Belymumab
Prednisone
Azathioprine
Methotrexate
Mycophenolate
mofetil
Prednisone/
Methylprednisolone
Mycophenolate
mofetil
Cyclophosphamide
Azathioprine
Plasmapheresis
IVIg
Rituximab
Arthritis
Serositis
Crops of mout
ulcers
Renal
Cerebral features
Alveolar hemorrhage
Hemolytic anemia
Thrombocytopenia
Necrotizing vasculitis
Severe serositis
Moderate
Comorbidity assessment
Treatment
Severe
Figure  2  Stepwise  approach  in  the  treatment  of  SLE.
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sHow  I  diagnose  and  treat  lupus  
avoid  Echinacea,  melatonin,  garlic,  and  alfalfa  sprouts,
which  have  been  described  to  precipitate  their  condition.22
It  is  also  important  to  inform  patients  to  avoid  disease
reactivation  drugs  such  as  procainamide,  hydralazine,  sul-
fonamides,  anti-TNFa,  ibuprofen  or  estrogen.23,24 Smoking
also  appears  to  inﬂuence  the  onset  and  course  of  the  dis-
ease  among  patients  with  SLE.25,26 The  effect  of  drugs
like  methotrexate  (MTX)  and  hydroxychloroquine  (HCQ)  may
diminish  with  smoking.
The  vaccination  schedule  in  SLE  patients  includes  a  yearly
inﬂuenza  vaccine  and  a  pneumococcal  vaccine  every  5  years.
Hepatitis  B  and  Tetanus  toxoid  vaccinations  also  seem  to
be  safe,  and  not  associated  with  ﬂares.27 The  quadrivalent
human  papillomavirus  vaccine  is  also  safe  and  not  asso-
ciated  with  increased  lupus  activity.28 It  is  important  to
consider  that  inactivated  live  vaccines  are  contraindicated
in  patients  taking  immunosuppressive  drugs  and/or  gluco-
corticoids  at  a  dose  >20  mg/day.27
Most  SLE  patients  are  diagnosed  in  the  reproductive
years,  thus  reproductive  health  is  an  important  issue.  It  is
recommended  for  SLE  patients  to  have  an  inactive  disease
for  a  six  month  period  prior  to  conception.  There  are  three
main  types  of  contraceptives:  barrier  methods,  intrauter-
ine  devices  and  the  hormonal  method.  Hormonal  methods
include  combined  or  progestin-only.  The  use  of  combined
methods  is  associated  with  an  increased  risk  of  SLE,29 how-
ever,  progesterone  methods  have  proven  to  be  safe  for  SLE
patients.30
In  addition  to  the  control  of  the  disease,  SLE  patients
should  have  a  systematic  assessment  of  comorbidities.  SLE
patients  develop  premature  atherosclerosis  and  their  risk
of  heart  attack  and  stroke  is  10  times  higher  than  that
of  age-matched  controls.31 Atherosclerosis  is  the  result
of  the  complex  interplay  between  dysfunctional  immune
regulation,  inﬂammation,  traditional  risk  factors,  aberrant
endothelial  cell  function  and  repair,  and  the  therapeutics  for
treating  the  underlying  autoimmune  disease.32 SLE  patients
also  have  an  increased  risk  of  different  types  of  cancer  such
as  non-Hodgkin  lymphoma,  lung  cancer,  and  cervical  dyspla-
sia.  Lupus  disease  activity,  smoking  and  immunosuppressive
drug  exposure  are  some  of  the  causes  of  the  increase  in
cancer  risk.33 Therefore,  SLE  patients  should  have  colonos-
copies,  Pap  smear,  and  mammogram  schedules.
Cognitive  dysfunction  prevalence  in  SLE  ranges  from
12%  to  87%.  Petri  et  al.  compared  cognitive  functioning
in  recently  diagnosed  SLE  patients  versus  normal  controls.
Using  Automated  Neuropsychological  Assessment  Metrics
(ANAM),  SLE  patients  performed  signiﬁcantly  worse  than
normal  controls.  Therefore,  a  cognitive  assessment  is  nec-
essary  in  all  SLE  patients  from  the  onset  of  the  disease.
We  can  divide  SLE  into  three  categories  based  on  disease
severity:  mild,  moderate,  and  severe  (Fig.  2).
Corticosteroids  (CS)  are  the  mainstay  of  treatment
for  SLE  in  any  category,  with  proven  efﬁcacy.34 The
dose  varies  according  to  the  severity  of  symptoms.  A
low  dose  is  0.1--0.2  mg/kg/day,  an  intermediate  dose  is
0.3--0.5  mg/kg/day,  and  a  high  dose  is  0.6--2  mg/kg/day.  The
use  of  this  drug  is  associated  with  an  increase  in  serum  lipids,
blood  pressure,  weight  and  glucose,  in  addition  to  cataracts
and  osteoporotic  fractures.  The  adverse  side  effects  of  CS
depend  on  both  the  current  and  the  cumulative  dosage.
Thamer  et  al.  demonstrated  the  hazard  ratio  for  accrued
m
a
r
aSAID, Nonsteroidal  antiinﬂammatory  drugs;  IVIg,  intravenous
mmunoglobulin;  SLE,  systemic  lupus  erythematosus.
rgan  damage  to  be  1.5,  1.64  and  2.51  with  prednisone  doses
f  6  mg/day,  12  mg/day  and  >18  mg/day,  respectively.35 It
s  important  to  note  that  SLE  diagnosis  is  not  equivalent
o  the  use  of  methylprednisolone,  and  that  in  many  cases
he  deleterious  effects  of  CS  may  outweigh  the  beneﬁts.
herefore,  the  goal  is  the  use  of  CS  according  to  the  clinical
anifestations  and  slow  tapering  to  1--2  mg/day.  In order  to
educe  CS  doses  and  side  effects,  the  use  of  another  agent
s  mandatory.34
Mild  SLE  includes  mucocutaneous  lesions,  arthralgias  and
atigue.  Sun  protection  consists  of  avoiding  when  the  sun
s  at  its  highest  (10  am  to  4  pm)  and  patients  should  use
gents  with  a  sun  protection  factor  of  at  least  50,  applied
0--30  min  prior  to  exposure,  and  reapplied  every  4  h.  Topical
herapies  depend  on  whether  it  is  a  localized  or  widespread
kin  disease.  Therapies  include  steroids  and/or  calcineurin
nhibitors.36 Systemic  therapies  include  antimalarial  agents,
TX,  azathioprine,  mycophenolate  mofetil  (MMF),  dapsone,
nd  cyclophosphamide  (CYC),  and  are  used  in  refrac-
ory  diseases  or  in  poor  responses  to  treatment.34,36 For
utaneovascular  manifestations  (Raynaud  syndrome,  livedo
eticularis,  etc.)  the  use  of  cold-preventive  measures  and
alcium  channel  blockers  can  be  beneﬁcial.  Nonsteroidal
ntiinﬂammatory  drugs  (NSAID)  can  be  used  in  headaches,
yalgias,  arthralgias,  and  serositis.  NSAID  use  must  be
onitored;  side  effects  could  be  renal,  gastrointestinal  or
ardiovascular.  In  my  experience,  I  have  seen  severe  sec-
ndary  side  effects  such  as  aseptic  meningitis.  Ibuprofen  is
he  drug  most  frequently  involved  in  aseptic  meningitis,  but
ulindac  and  naproxen  have  also  been  described.37
Moderate  SLE  includes  arthritis,  serositis,  and  crops  of
outh  ulcers.  Arthritis  can  improve  with  NSAID,  moder-
te  doses  of  prednisone,  or  antimalarial  drugs.  When  the
esponse  is  poor,  MTX,  leﬂunomide,  azathioprine  and  TNF-
 agents  can  be  used.38 Serositis  (pleurisy,  pericarditis)
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22  
esponds  to  NSAID  and  CS.  Belimumab  is  a  fully  human-
zed  IgG1  mAb  that  binds  to  soluble  BLyS  (B  lymphocyte
timulator),  inhibiting  its  activity.21 BLISS-52  and  BLISS  76
emonstrated  signiﬁcant  clinical  responses  with  Belimumab
ompared  to  placebos  in  patients  with  mild  and  moderate
isease  activity  (without  nephritis/CNS).39,40
The  severe  SLE  stage  includes  hemolytic  anemia,
hrombocytopenia,  diffuse  alveolar  hemorrhage,  necrotiz-
ng  vasculitis,  neuropsychiatric  lupus  and  renal  involvement.
n  this  stage,  CS  is  used  in  high  doses  and  intravenous
ethylprednisolone  pulses  for  severe  cases.  In  hemolytic
nemia  and  thrombocytopenia  the  treatment  includes  CS
nd  danazol,  Rituximab,  intravenous  immunoglobulin  (IVIg),
MF,  CYC,  plasmapheresis  and/or  splenectomy  for  refrac-
ory  cases.41 The  use  of  CYC  and  high  doses  of  CS  are
lso  employed  for  diffuse  alveolar  hemorrhage,  and  plasma-
heresis  for  refractory  cases.  We  made  an  observational,
etrospective  study  that  included  twelve  SLE  patients  with
lveolar  hemorrhage.  We  found  that  simultaneous  treat-
ent  with  CS,  CYC,  plasmapheresis  and  IVIg  was  associated
ith  a  mortality  of  17%,  contrary  to  the  rate  previously
escribed  of  up  to  70--90%.42
According  to  the  recommendations,  glucocorticoid  and
mmunosuppressive  therapy  is  indicated  for  severe  neu-
opsychiatric  manifestations  (myelopathy,  optic  neuritis,
tc.).  Anticoagulation  therapy  is  indicated  for  the  SNC  man-
festations  of  antiphospholipid  syndrome.43 In  our  practice,
e  have  also  observed  that  the  combination  of  methylpred-
isolone,  CYC,  IVIg  and  Rituximab  was  effective  for  psychosis
efractory  to  conventional  treatment.
Renal  involvement  is  considered  the  most  important
rognostic  factor.  The  Task  Force  Panel  for  screening,
reatment,  and  management  of  Lupus  Nephritis  (LN)  rec-
mmended  the  treatment  to  be  based  on  the  type  of  LN
ccording  to  the  ISN/RPS  criteria.44 The  treatment  consists
f  the  use  of  corticosteroids  either  solely  or  in  combina-
ion  with  immunosuppressive  agents.  The  recommendations
or  LN  treatment  include  an  induction  and  a  maintaining
herapy.  There  are  2  regimens  for  Class  III/IV  LN,  low-
ose  ‘‘Euro-Lupus’’  CYC  and  high-dose  CYC  followed  by
aintenance  treatment  with  MMF  or  azathioprine.45 In  our
ractice,  we  believe  that  a  low-dose  CYC  is  more  beneﬁcial
o  patients  decreasing  adverse  effects,  such  as  infections,
onadal  toxicity  and  increased  risk  of  cancer.  We  do  not
hare  the  idea  that  methylprednisolone  pulses  will  provide
 greater  beneﬁt  than  prednisone.  And  ﬁnally,  LN  response
hould  be  evaluated  3--6  months  after  initiating  treatment.
In  conclusion,  SLE  is  a  challenging  disease  to  diagnose
nd  treat.  Advances  in  research  have  allowed  us  to  know
hich  individuals  are  at  risk  of  developing  the  disease.  Each
atient  should  be  treated  on  an  individualized  basis  accord-
ng  to  their  clinical  manifestations  in  order  to  provide  proper
reatment.
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